Extracellular matrix of ovarian tumors.
暂无分享,去创建一个
[1] G. Rosen,et al. Expression of Fibronectin and Its Cell Surface Receptors , 1991 .
[2] B. Toole,et al. Expression of Hyaluronan in human tumor progression , 2006, Journal of carcinogenesis.
[3] A. Skubitz,et al. Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells , 2004, Clinical & Experimental Metastasis.
[4] F. Hirahara,et al. Wide Distribution of Laminin-5 γ2 Chain in Basement Membranes of Various Human Tissues , 1998, Hormone Research in Paediatrics.
[5] Anthony J. Guidi,et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] C. Haglund,et al. Epithelial and stromal syndecan‐1 expression as predictor of outcome in patients with gastric cancer , 2001, International journal of cancer.
[7] D. Horsfall,et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] C. Sheehan,et al. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. , 2001, American journal of clinical pathology.
[9] V. Kosma,et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. , 2003, Clinical Cancer Research.
[10] A. Loercher,et al. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. , 1999, Cancer research.
[11] V. Kosma,et al. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. , 2000, Cancer research.
[12] V. Kosma,et al. Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosis , 2003, International journal of cancer.
[13] H. Dvorak,et al. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. , 1996, The American journal of pathology.
[14] H. Tamaki,et al. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] L. Hawthorn,et al. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. , 2005, Oncology reports.
[16] R. Ádány,et al. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. , 1990, The Journal of biological chemistry.
[17] P. Marynen,et al. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. , 1997, Genomics.
[18] P. Heitz,et al. Distribution of the large aggregating proteoglycan versican in adult human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[19] L. Heickendorff,et al. Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. , 2001, Clinical chemistry.
[20] R. Einspanier,et al. Hyaluronan in the bovine oviduct—modulation of synthases and receptors during the estrous cycle , 2004, Molecular and Cellular Endocrinology.
[21] D. Katsaros,et al. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells , 2002, Oncogene.
[22] A. Skubitz,et al. CD44 and β1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins , 2004, Clinical & Experimental Metastasis.
[23] L. Rodriguez-Rodriguez,et al. The CD44 receptor is a molecular predictor of survival in ovarian cancer , 2003, Medical oncology.
[24] A. Godwin,et al. Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity , 2002, Cancer.
[25] J. McDonald,et al. Characterization and Molecular Evolution of a Vertebrate Hyaluronan Synthase Gene Family* , 1998, The Journal of Biological Chemistry.
[26] J. Risteli,et al. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas. , 1996, The American journal of pathology.
[27] J. Rabczyński,et al. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. , 2004, Gynecologic oncology.
[28] P. Mullen,et al. Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines , 1999, British Journal of Cancer.
[29] M. Hung,et al. Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth* , 2001, The Journal of Biological Chemistry.
[30] K. Sobolewski,et al. Accumulation of collagen in ovarian benign tumours. , 1999, Acta biochimica Polonica.
[31] O. Dapunt,et al. Prognostic value of CD44 splice variant expression in ovarian cancer. , 1995, Oncology.
[32] Mitsuaki Suzuki,et al. Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.
[33] J. Weinberg,et al. Increased levels of laminin in ascitic fluid of patients with ovarian cancer. , 1995, Cancer letters.
[34] L. Zardi,et al. Fibronectin as target for tumor therapy , 2006, International journal of cancer.
[35] U. Schumacher,et al. Expression of hyaluronate and hyaluronate synthase in human primary tumours and their metastases in scid mice. , 2002, Cancer letters.
[36] V. Kosma,et al. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. , 2002, Cancer research.
[37] J. Niloff,et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Labat-Robert,et al. Fibronectin in malignancy. , 2002, Seminars in cancer biology.
[39] H. Heinzl,et al. Prognostic value of laminin-5 in serous adenocarcinomas of the ovary. , 2002, Anticancer Research.
[40] U. Puistola,et al. Aminoterminal propeptide of type III procollagen in ovarian cancer , 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.
[41] I. Weber,et al. Model Structure of Decorin and Implications for Collagen Fibrillogenesis* , 1996, The Journal of Biological Chemistry.
[42] H. Rochefort,et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Langdon,et al. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. , 1996, British Journal of Cancer.
[44] É. Álvarez,et al. Splice variant expression of CD44 in patients with breast and ovarian cancer. , 2001, Oncology reports.
[45] M. Weber,et al. Basement membrane proteins. , 1992, Kidney international.
[46] V. Hascall,et al. Localization and synthesis of hyaluronic acid in the cumulus cells and mural granulosa cells of the preovulatory follicle. , 1992, Developmental biology.
[47] A. J. Day,et al. Hyaluronan-binding Proteins: Tying Up the Giant* , 2002, The Journal of Biological Chemistry.
[48] E. Lillehoj,et al. Normal and abnormal aspects of proteinuria. Part I: Mechanisms, characteristics and analyses of urinary protein. Part II: Clinical considerations. , 1986, Experimental pathology.
[49] J. Sanes,et al. A simplified laminin nomenclature. , 2005, Matrix biology : journal of the International Society for Matrix Biology.
[50] T. Wight,et al. Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.
[51] P. Prehm. Release of hyaluronate from eukaryotic cells. , 1990, The Biochemical journal.
[52] Scully Re,et al. World Health Organization classification and nomenclature of ovarian cancer. , 1975, National Cancer Institute monograph.
[53] R. Rodgers,et al. Characterization of the expression of the alternative splicing of the ED-A, ED-B and V regions of fibronectin mRNA in bovine ovarian follicles and corpora lutea. , 1999, Reproduction, Fertility and Development.
[54] P. Speiser,et al. CD-44 is not involved in the metastatic spread of ovarian cancer in vivo. , 1995, Anticancer research.
[55] David I. Smith,et al. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. , 2002, Cancer research.
[56] M. Tammi,et al. Hyaluronan and Homeostasis: A Balancing Act* , 2002, The Journal of Biological Chemistry.
[57] V. Hascall,et al. Coding sequence of a hyaluronan synthase homologue expressed during expansion of the mouse cumulus-oocyte complex. , 1997, Archives of biochemistry and biophysics.
[58] E. Hay,et al. Cell Biology of Extracellular Matrix , 1988, Springer US.
[59] M. Barbareschi,et al. High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis , 2003, Cancer.
[60] M. L. Harland,et al. A novel basal lamina matrix of the stratified epithelium of the ovarian follicle. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[61] J. Risteli,et al. Immunohistochemical study of type I collagen and type I pN‐collagen in benign and malignant ovarian neoplasms , 1995, Cancer.
[62] U. Puistola,et al. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. , 1993, Cancer research.
[63] J. Risteli,et al. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study , 1993, Cancer.
[64] T. Kaku,et al. Histological classification of ovarian cancer , 2003, Medical Electron Microscopy.
[65] M. Deavers,et al. The expression of decorin in human ovarian tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] J. Risteli,et al. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. , 2001, Gynecologic oncology.
[67] W. Knudson,et al. Hyaluronan‐binding proteins in development, tissue homeostasis, and disease , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] E. Ruoslahti,et al. Hyaluronate binding properties of versican. , 1992, The Journal of biological chemistry.
[69] R. Timpl,et al. Biglycan and Decorin Bind Close to the N-terminal Region of the Collagen VI Triple Helix* , 2001, The Journal of Biological Chemistry.
[70] Y. Kawarada,et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[71] G. Jayson,et al. Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer , 2004, Clinical Cancer Research.
[72] L. Bourguignon,et al. CD44 Interaction with c-Src Kinase Promotes Cortactin-mediated Cytoskeleton Function and Hyaluronic Acid-dependent Ovarian Tumor Cell Migration* , 2001, The Journal of Biological Chemistry.
[73] A. Rapraeger,et al. Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.
[74] M. Aziz,et al. Clinical Evaluation of Serum Aminoterminal Propeptide of Type III Procollagen as Tumor Marker in Gynecologic Malignancies , 1993, Tumori.
[75] P. Schwartz,et al. Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival. , 2002, Gynecologic oncology.
[76] P. Clement,et al. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament: Atlas of Tumor Pathology , 1999 .
[77] R. Iozzo. Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.
[78] D. Horsfall,et al. Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer , 2004, Clinical Cancer Research.
[79] Donald R Schwartz,et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. , 2003, Cancer cell.
[80] S. Cannistra,et al. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. , 1997, Cancer research.
[81] A. Freedman,et al. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[82] J. Filmus,et al. Glypicans in growth control and cancer. , 2001, Glycobiology.
[83] K. Münstedt,et al. Association between fibronectin expression and prognosis in ovarian carcinoma. , 2003, Anticancer research.
[84] K. Kimata,et al. Hyaluronan synthase expression in ovarian cancer. , 2004, Oncology reports.
[85] T. Kiviluoto,et al. Laminin alpha1-chain shows a restricted distribution in epithelial basement membranes of fetal and adult human tissues. , 2000, Experimental cell research.
[86] A. D. de Agostini,et al. Anticoagulant heparan sulfate proteoglycans expression in the rat ovary peaks in preovulatory granulosa cells. , 2001, Glycobiology.
[87] J. Risteli,et al. Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo , 1999, British Journal of Cancer.
[88] R. Rodgers,et al. Development of the ovarian follicular epithelium , 1999, Molecular and Cellular Endocrinology.
[89] P. Delmas,et al. Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain , 1999, Journal of cellular biochemistry.
[90] S. Ochsner,et al. Processing and Localization of ADAMTS-1 and Proteolytic Cleavage of Versican during Cumulus Matrix Expansion and Ovulation* , 2003, Journal of Biological Chemistry.
[91] R. Iozzo,et al. An Anti-oncogenic Role for Decorin , 2000, The Journal of Biological Chemistry.
[92] M J Bissell,et al. Tissue architecture: the ultimate regulator of epithelial function? , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[93] R. Iozzo,et al. Decorin prevents metastatic spreading of breast cancer , 2005, Oncogene.
[94] H. Saito,et al. Syndecan-4 expression is associated with follicular atresia in mouse ovary , 1999, Histochemistry and Cell Biology.
[95] A. Friedl,et al. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis , 2006, Oncogene.
[96] D. Russell,et al. Extracellular matrix of the developing ovarian follicle. , 2003, Reproduction.
[97] E. Vuorio,et al. Cyclic expression of mRNA transcripts for connective tissue components in the mouse ovary. , 1999, Molecular human reproduction.
[98] L. Bourguignon,et al. Hyaluronan-CD44 Interaction with IQGAP1 Promotes Cdc42 and ERK Signaling, Leading to Actin Binding, Elk-1/Estrogen Receptor Transcriptional Activation, and Ovarian Cancer Progression* , 2005, Journal of Biological Chemistry.
[99] C. Christiansen,et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.
[100] G. Jayson,et al. Heparan sulfate proteoglycans and cancer , 2001, British Journal of Cancer.
[101] G. Keszler,et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. , 2005, Anticancer research.
[102] Markku Santala,et al. Type I and Type III Collagen Metabolites as Predictors of Clinical Outcome in Epithelial Ovarian Cancer , 1999 .
[103] J. Risteli,et al. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[104] P. Kruk,et al. Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. , 1991, Biology of reproduction.
[105] R. Einspanier,et al. Expression of Hyaluronan Synthases and Corresponding Hyaluronan Receptors Is Differentially Regulated During Oocyte Maturation in Cattle1 , 2003, Biology of reproduction.
[106] R. Iozzo. Perlecan: a gem of a proteoglycan. , 1994, Matrix biology : journal of the International Society for Matrix Biology.
[107] Y. Sado,et al. Distribution of the α1 to α6 Chains of Type IV Collagen in Bovine Follicles , 1998 .
[108] A. Godwin,et al. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis , 2002, Cancer.
[109] T. Pihlajaniemi,et al. Differential Expression of Laminin Isoforms in Ovarian Epithelial Carcinomas Suggesting Different Origin and Providing Tools for Differential Diagnosis , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[110] R. Chiquet‐Ehrismann. Tenascin and other adhesion-modulating proteins in cancer. , 1993, Seminars in cancer biology.
[111] R. Timpl,et al. Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. , 1993, Experimental cell research.
[112] P. Marynen,et al. Glypican-6, a New Member of the Glypican Family of Cell Surface Heparan Sulfate Proteoglycans* , 1999, The Journal of Biological Chemistry.
[113] F. Stenbäck. Collagen type III in ovarian tumors. Histological, immunohistochemical and ultrastructural findings. , 1989, European journal of obstetrics, gynecology, and reproductive biology.
[114] A. Skubitz,et al. CD44 and β1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells , 1999 .
[115] B. Werness,et al. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. , 2001 .
[116] J. Schittny,et al. Molecular architecture of basement membranes , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[117] G. Turner,et al. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis , 1996, Clinical & Experimental Metastasis.
[118] J. Risteli,et al. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125. , 2000, Anticancer research.
[119] R. Kokenyesi. Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix , 2001, Journal of cellular biochemistry.
[120] P. Pujol,et al. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. , 1998, The American journal of pathology.
[121] R. Timpl,et al. Supramolecular assembly of basement membranes , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.
[122] P. Leung,et al. Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.
[123] M. Schmitt,et al. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. , 1988, Cancer research.
[124] A. Charchanti,et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. , 2004, Journal of experimental & clinical cancer research : CR.
[125] J. Risteli,et al. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. , 2003, Gynecologic oncology.
[126] F. Stenbäck,et al. Basement membrane structures in tumors of the ovary. , 1985, European journal of obstetrics, gynecology, and reproductive biology.
[127] M. Paulsson,et al. Basement membrane proteins: structure, assembly, and cellular interactions. , 1992, Critical reviews in biochemistry and molecular biology.